A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160
This study is recruiting at 13 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Incyte Corporation
- Last updated on ClinicalTrials.gov
- July 22, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic Hospital · Phoenix, AZ
California · 2
- Stanford University · Palo Alto, CA
- UCLA Healthcare Hematology-Oncology · Santa Monica, CA
Colorado · 1
- Sarah Cannon Research Institue At Healthone · Denver, CO
Florida · 1
- Florida Cancer Specialists · Sarasota, FL
Maryland · 1
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins · Baltimore, MD
Massachusetts · 1
- Dana Farber Cancer Institute · Boston, MA
New Jersey · 1
- Hackensack University Medical Center · Hackensack, NJ
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- Weill Cornell Medicine · New York, NY
Pennsylvania · 1
- Jefferson University Hospitals · Philadelphia, PA
Tennessee · 1
- Scri Oncology Partners · Nashville, TN
Texas · 1
- Md Anderson Cancer Center · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.